Casimersen
HealthData.Gov
Updated Oct 29, 2026
About this dataset
AMONDYS 45 (casimersen) is an intravenous solution used to treat Duchenne muscular dystrophy in patients with a specific genetic mutation. It works as an antisense oligonucleotide to increase protein synthesis. Manufactured by Sarepta Therapeutics, Inc., it's available as a 50 mg/mL injection in single-use vials. This information was generated using AI and is provided for informational and research purposes only.
Data and resources (1)
- HTML
Casimersen
Access the FDA dataset for Casimersen — ANDA 213026 submitted by Mylan Institutional LLC
Modified Apr 29, 2026